We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Delays NDA of Supernus’ Parkinson’s Disease Infusion Device a Second Time
FDA Delays NDA of Supernus’ Parkinson’s Disease Infusion Device a Second Time
The FDA has pushed back once again on Supernus Pharmaceuticals’ New Drug Application (NDA) for its investigational apomorphine infusion device, designed to continuously treat motor fluctuations in Parkinson’s disease (PD).
